Viridian Therapeutics, Inc./DE (VRDN) Operating margin 2016–2025
Viridian Therapeutics, Inc./DE (VRDN) operating margin by fiscal year — reported operating income divided by reported revenue.
-512.9%FY2025 · since FY2016: -488.6% → -512.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -512.9% | +98505.3 pp |
| FY2024 | -99018.2% | -17983.2 pp |
| FY2023 | -81035.0% | -73455.8 pp |
| FY2022 | -7579.2% | -4888.4 pp |
| FY2021 | -2690.8% | +7821.6 pp |
| FY2020 | -10512.4% | -9571.4 pp |
| FY2019 | -941.0% | -546.5 pp |
| FY2018 | -394.5% | +268.3 pp |
| FY2017 | -662.8% | -174.2 pp |
| FY2016 | -488.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More VRDN financial trends
VRDN RevenueVRDN Net incomeVRDN Net marginVRDN Gross profitVRDN Gross marginVRDN Operating incomeVRDN Operating cash flowVRDN Free cash flowVRDN Capital expendituresVRDN Return on equityVRDN Stock buybacksVRDN Dividends paidVRDN Total assetsVRDN Total liabilitiesVRDN Shareholders’ equityVRDN overview →